FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LaFrance Norman D.</u>				2. Issuer Name and Ticker or Trading Symbol PLUS THERAPEUTICS, INC. [ PSTV ]						eck all applic Directo	cable) or	erson(s) to Iss	vner			
(Last)	,	rst) PEUTICS INC.	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/22/2024							below)	cer (give title Other (specify below)  Chief Medical Officer		
4200 MARATHON BOULEVARD, SUITE 200			4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) AUSTIN	T2	X	78756											led by More ti	eporting Personan One Repo	
(City)	(Si	tate)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication										
						Check this box to indicate that a transaction was made pursuant to a contract, instr satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							truction or written plan that is intended to			
		Tab	le I - Nor	ı-Deriv	vativ	e Se	curities	Ac	quired, Di	isposed c	f, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)		ed (A) or tr. 3, 4 and		es Form ally (D) of following (I) (II	rm: Direct	7. Nature of Indirect Beneficial Ownership				
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Execu (Month/Day/Year) if any	3A. Deemee Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.03	02/22/2024			A		24,073		(1)	02/22/2034	Common Stock	24,073	\$0.00	24,073	D	

## **Explanation of Responses:**

1. The options vest over four years in equal 1/48th increments on each monthly anniversary of the issuance date, and vest upon a change of control event in accordance with the Reporting Person's employment agreement.

/s/ Andrew Sims, attorney-in-

fact

\*\* Signature of Reporting Person

Date

02/26/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.